

Paxman's global distribution network grows with addition of two new partners for Chile and Ukraine

Paxman today announce Sistemplus S.A. as their exclusive distribution partner for the new territory of Chile, and Medinova LLC as their global distribution partner for Paxman equipment in Ukraine.

Headquartered in Chile's capital, Santiago, Sistemplus S.A. are well placed to introduce scalp cooling to the Chilean market with their existing strong relationships with key reference Doctors, private and public hospitals and Oncology Groups.

A relatively small country, Chile has a population of over 19 million however has a very high Human Development Index (HDI) being ranked 43 out of 189 countries and territories

Breast cancer is the most common cancer site by both incidence and mortality in women in Chile with a new breast cancer diagnosis every three hours and three women dying every day. The highest cancer incidence for men is prostate cancer, and stomach cancer is the most common cause of death in men. In 2018, there were 5393 breast cancer diagnoses in Chile.

In 2018, the country launched its 10-year National Cancer Plan with an anticipated investment of USD \$25 million in equipment and infrastructure across the country, to include 11 new cancer centres. 2022 will see the deployment of 130 Oncologists by the Ministry of Health and, importantly, the launch the National Cancer Registry.

Based in Kiev, Medinova LLC are ready to launch the Paxman Scalp Cooling System (PSCS) to oncology centres across Ukraine, adding Paxman to their portfolio for the representation of world-leading medical devices and products. Medinova's strong reputation stands them in a good position for the introduction of scalp cooling treatment to their established client-base across Ukraine.

With a population of 43,514,481, cancer is the second leading cause of death, in the country, accounting for 12% of the total. There are 326 new cases of cancer per 100 000 per year. Cancer prevalence is 1.7%. Breast cancer is the most prevalent cancer in females accounting for 82 451 cases in 2020.

Ukraine has a well-established network of private, specialised oncology clinics and whilst healthcare in the country is part of a guaranteed, universal free of charge healthcare system, in practice most people contribute to the cost of their treatment. The transformation is underway with a switch to a public healthcare system based on insurance-based medicine.

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

[Paxman's global distribution network grows with addition of two new partners for Chile and Ukraine](#)